Edgewise Therapeutics (EWTX) Stock Forecast, Price Target & Predictions
EWTX Stock Forecast
Edgewise Therapeutics stock forecast is as follows: an average price target of $48.00 (represents a 154.91% upside from EWTX’s last price of $18.83) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
EWTX Price Target
The average price target for Edgewise Therapeutics (EWTX) is $48.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $48.00 to $48.00. This represents a potential 154.91% upside from EWTX's last price of $18.83.
EWTX Analyst Ratings
According to 1 Wall Street analysts, Edgewise Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for EWTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Edgewise Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Yasmeen Rahimi | Piper Sandler | $48.00 | $18.01 | 166.52% | 154.91% |
The latest Edgewise Therapeutics stock forecast, released on Jul 01, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $48.00, which represents a 166.52% increase from the stock price at the time of the forecast ($18.01), and a 154.91% increase from EWTX last price ($18.83).
Edgewise Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $48.00 | $48.00 |
| Last Closing Price | $18.83 | $18.83 | $18.83 |
| Upside/Downside | -100.00% | 154.91% | 154.91% |
In the current month, the average price target of Edgewise Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Edgewise Therapeutics's last price of $18.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 01, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Edgewise Therapeutics's last stock rating was published by Piper Sandler on Jul 01, 2024. The company gave EWTX a "Overweight" rating, the same as its previous rate.
Edgewise Therapeutics Financial Forecast
Edgewise Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Edgewise Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. EWTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Edgewise Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict EWTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Edgewise Therapeutics's previous annual EBITDA (undefined) of $NaN.
Edgewise Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-47.47M | $-43.06M | $-39.65M | $-36.03M | $-37.08M | $-34.98M | $-32.26M |
| High Forecast | $-47.47M | $-43.06M | $-39.65M | $-36.03M | $-37.08M | $-31.30M | $-32.26M |
| Low Forecast | $-47.47M | $-43.06M | $-39.65M | $-36.03M | $-37.08M | $-38.66M | $-32.26M |
| Surprise % | - | - | - | - | - | - | - |
Edgewise Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EWTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Edgewise Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Edgewise Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to EWTX last annual SG&A of $NaN (undefined).
Edgewise Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.51 | $-0.46 | $-0.42 | $-0.39 | $-0.40 | $-0.37 | $-0.34 |
| High Forecast | $-0.51 | $-0.46 | $-0.42 | $-0.39 | $-0.40 | $-0.33 | $-0.34 |
| Low Forecast | $-0.51 | $-0.46 | $-0.42 | $-0.39 | $-0.40 | $-0.41 | $-0.34 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Edgewise Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EWTX previous annual EPS of $NaN (undefined).
Edgewise Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| ACET | Adicet Bio | $1.49 | $32.50 | 2081.21% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| XLO | Xilio Therapeutics | $0.82 | $7.00 | 753.66% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| VOR | Vor Biopharma | $1.05 | $6.00 | 471.43% | Buy |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
EWTX Forecast FAQ
Is Edgewise Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Edgewise Therapeutics (EWTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of EWTX's total ratings.
What is EWTX's price target?
Edgewise Therapeutics (EWTX) average price target is $48 with a range of $48 to $48, implying a 154.91% from its last price of $18.83. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Edgewise Therapeutics stock go up soon?
According to Wall Street analysts' prediction for EWTX stock, the company can go up by 154.91% (from the last price of $18.83 to the average price target of $48), up by 154.91% based on the highest stock price target, and up by 154.91% based on the lowest stock price target.
Can Edgewise Therapeutics stock reach $30?
EWTX's average twelve months analyst stock price target of $48 supports the claim that Edgewise Therapeutics can reach $30 in the near future.
What are Edgewise Therapeutics's analysts' financial forecasts?
Edgewise Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-104M (high $-101M, low $-108M), average SG&A $0 (high $0, low $0), and average EPS is $-1.116 (high $-1.076, low $-1.155). EWTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-166M (high $-166M, low $-166M), average SG&A $0 (high $0, low $0), and average EPS is $-1.777 (high $-1.777, low $-1.777).